Results 51 to 60 of about 7,390 (165)

Ocrelizumab-Induced Severe Colitis

, 2020
We report a case of severe ocrelizumab (anti-CD20 monoclonal antibody) induced colitis in a 43-year-old woman with multiple sclerosis leading to total colectomy after failing medical therapy.
Daniel Bermingham, Hsing Hwa Lee, Naveen Sritharan, Gabriela Strey   +3 more
core   +1 more source

Association Between Neurofilament Light Chain and Real‐World Ambulatory Function in Progressive MS

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Neurofilament light chain (NfL) is a biomarker of neuroaxonal injury in multiple sclerosis (MS), yet associations with functional outcomes remain unclear. Longitudinal associations between serum NfL (sNfL) and daily step count (STEPS) from wearable devices were assessed in a large international progressive MS cohort.
Gabby B. Joseph, Megan McCune, Riley Bove, Ahmed Abdelhak, Bruce A. C. Cree, Valerie J. Block   +5 more
wiley   +1 more source

Efficacy of accelerated vaccination against Hbv to achieve antibody formation in multiple sclerosis patients receiving anti-Cd20 therapy

Annals of Indian Academy of Neurology, 2023
Aim: Ocrelizumab is a monoclonal antibody that has been approved for use in both relapsing–remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS).
Emine Rabia Koc, Omer Faruk Turan, Furkan Saridas, Bedirhan Menguc, Sema Nur Minaz, Guven Ozkaya   +5 more
doaj   +1 more source

Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis

British Journal of Clinical Pharmacology, EarlyView.
Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley   +1 more source

Viral pericarditis following ocrelizumab in a multiple sclerosis patient

, 2023
Ocrelizumab is a humanized monoclonal anti-CD20 antibody, approved for the treatment of relapsing and primary-progressive multiple sclerosis. We reported a case of pericarditis in an RRMS patient treated with ocrelizumab, who presented with chest pain ...
Miele, Giuseppina, Bonavita, Simona, Giuseppina Miele, Simona Bonavita, Abbadessa, Gianmarco, Elisabetta Maida, Maida, Elisabetta, Gianmarco Abbadessa   +7 more
core   +1 more source

The Impact of Common Medications on Male Fertility: An Updated Systematic Review

Andrology, EarlyView.
ABSTRACT Background Compared with those of cytotoxic treatments, the potential effects of common medications on the fertility of men trying to conceive currently or planning to conceive in the future are less well described. The use of common medications may modify the gonadotropic axis, spermatogenesis, and epididymal maturation or alter male ...
Lina Jebli, Salomé Gallissian, Roxanne Barèges, Félicia Fournier, Catherine Metzler‐Guillemain, Ségolène Prades, Fanny Magnan‐Sebag, Jeanne Perrin   +7 more
wiley   +1 more source

Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis [PDF]

, 2023
Background and objectivesOcrelizumab improved clinical and MRI measures of disease activity and progression in three phase 3 multiple sclerosis (MS) studies. Post hoc analyses demonstrated a correlation between the ocrelizumab serum concentration and the
Manfrini, Marianna, Koendgen, Harold, Hauser, Stephen L., Bar-Or, Amit, Mercier, Francois, Weber, Martin S., Weber, Martin S, Hauser, Stephen, Hauser, Stephen L, Günther, Andreas, Kappos, Ludwig, Kletzl, Heidemarie, Wing, Qing, Weber, Martin, Petry, Claire, Smith, Terence, Model, Fabian   +16 more
core   +1 more source

Recovery of Chronic Inflammatory Demyelinating Polyneuropathy on Treatment With Ocrelizumab in a Patient With Co-Existing Multiple Sclerosis

Journal of Central Nervous System Disease, 2022
The chimeric anti-CD20 antibody rituximab has demonstrated good efficacy as an off-label treatment in chronic inflammatory demyelinating polyneuropathy (CIDP), while the humanized anti-CD20 antibody ocrelizumab has been approved for treatment of multiple
Michael Auer MD PhD, Harald Hegen MD PhD PD, Anna Hotter MD, Wolfgang Löscher MD MSc, Klaus Berek MD, Anne Zinganell MD, Elena Fava MD, Paul Rhomberg MD, Florian Deisenhammer MD MSc, Franziska Di Pauli MD PhD   +9 more
doaj   +1 more source

The results of ocrelizumab therapy in patients with multiple sclerosis in the Voronezh region

Клинический разбор в общей медицине, 2023
Aim. Analysis of own results of ocrelizumab therapy in patients with multiple sclerosis (MS) in the Voronezh region. Materials and methods. This work was a cross-sectional study based on the Voronezh Regional Clinical Hospital № 1. The study included 61
Valeriya A. Bykova , Nataliya A. Ermolenko , Olga N. Krasnorutskaya, Anna O. Khoroshikh, Ekaterina A. Yazova , Nataliya V. Tkachenko, Oxana V. Bragina   +6 more
doaj   +1 more source

Benign by design: A paradigm shift in cosmetic ingredient development

International Journal of Cosmetic Science, EarlyView.
Benign by design strategies enable the creation of biodegradable cosmetic ingredients, reducing environmental persistence while maintaining the intended biological activity. This work compiles design rules and tools to guide the development of more sustainable molecules for the cosmetics industry.
Sandra Mota, Klaus Kümmerer, Isabel Martins de Almeida, Emília Sousa   +3 more
wiley   +1 more source